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Abstract
Background and Purpose Inﬂammatory bowel disease
(IBD) consists of ulcerative colitis (UC) and Crohn’s dis-
ease (CD), which are complex genetic disorders resulting
from the interplay between several genetic and environ-
mental risk factors. The arylamine N-acetyltransferase 2
(NAT2) enzyme detoxiﬁes a wide spectrum of naturally
occurring xenobiotics including carcinogens and drugs.
Acetylation catalyzed by NAT2 is an important process in
metabolic activation of arylamines to electrophilic inter-
mediates that initiate carcinogenesis. The aim of our study
was to determine whether there is any association between
the susceptibility to inﬂammatory bowel disease among the
variations of NAT2 genotypes.
Methods This study was carried out in 80 patients with
IBD. The control group consisted of 100 healthy volun-
teers. The most common mutations found in the Caucasian
population are at the positions 481T, 803G, 590A and
857A on the NAT2 gene. This was determined using the
polymerase chain reaction–restriction fragment length
polymorphism method with DNA extracted from periphe-
ral blood.
Results Risk of IBD development was 3.86 for the car-
riers of the NAT2*5/NAT2*7 genotype and 2.53 for the
carriers with NAT2*6/NAT2*7, but it was not statistically
signiﬁcant. A statistically signiﬁcant correlation between
the NAT2*7 allele prevalence and the risk for developing
IBD was found (OR = 5.8; P = 0.005).
Conclusions Higher prevalence of the NAT2*7 allele in
patients with IBD and the obtained OR values could sug-
gest that this mutation has the effect of increasing IBD
development. Future studies are needed to conﬁrm our
assumptions on larger group of patients.
Keywords Inﬂammatory bowel disease  NAT2  Genetic
polymorphism
Introduction
Inﬂammatory bowel disease (IBD) is a term encompassing
a group of chronic inﬂammatory diseases of unknown
etiology which affect the gastrointestinal tract. They
include Crohn’s disease (CD) and ulcerative colitis (UC)
[1]. Both diseases are considered non-speciﬁc since their
causative factors remain unknown. Genetic, immunologic,
bacterial, environmental, and psychological factors are
believed to be factors in the pathogenesis [2]. The role of
genetic factors is supported by race/ethnic difference, e.g.
IBD occurs with higher frequency in the Caucasian race
[3]. Higher morbidity was observed when it occurred
within the same families, especially in the ﬁrst-degree
relatives (30–100 times higher) and in the monozygotic
twins [4]. In the studies on the genetic basis of inﬂamma-
tory bowel disease, HLA class II encoding genes and their
relationship with some regions of chromosomes 1, 5, 6, 12,
14, 16, 19 are also considered [4, 5]. Taking into account
that both genetic and environmental factors play a role in
the pathogenesis of inﬂammatory bowel disease, it would
be interesting to determine if there is any relation between
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N-acetyltransferase 2 (NAT2) is a II-phase biotransfor-
mation enzyme responsible for detoxiﬁcation of xenobiot-
ics which have the structure of aromatic amines, hydrazine,
sulphonamides and aliphatic amines. NAT 2 takes part in
the acetyl group transfer from the co-enzyme A to the
hydrophobic substrates, increasing their solubility. Car-
cinogenic and mutagenic compounds may be produced as a
result of these reactions. Arylamines and hydrazines, fre-
quently occurring in the environment, may contribute to
the pathogenesis of numerous diseases [6–8].
NAT2activityisgeneticallydeterminedandisdependent
on patient’s genotype resulting from the presence of
two alleles in the NAT2 gene, which is localized on chro-
mosome 8 where various point mutations may occur. A
regularly updated list of NAT2 gene alleles is presented by
the UniversityofLouisvilleontheir website:http://louisville.
edu/medschool/pharmacology web page [9]. A majority of
the mutated alleles of NAT2 encode a protein of the reduced
enzymatic activity [10–12].
The acetylation genotype is believed to predispose a
patient to numerous diseases. The role of NAT2 polymor-
phism was investigated in prostate cancer, gastrointestinal
tract cancer, urinary bladder cancer, systemic lupus ery-
thematosus (SLE), endometriosis, Parkinson’s and Alzhei-
mer’s disease [13–18]. However, there are few reports on
the inﬂuence of the acetylation genotype on the morbidity
of IBD. Our study is the ﬁrst that estimates the distribution
of NAT2 genotypes in patients suffering from inﬂammatory
bowel disease in Poland. A study of the NAT2 genotype
may broaden our knowledge of the genetic etiology and
pathogenesis of IBD, and provide important data, which
may be useful in the diagnostics and treatment of IBD.
Patients and Methods
Eighty patients with inﬂammatory bowel disease, treated at
the Department of General and Colorectal Surgery of the
Medical University of Lodz, were included in the study. A
total of 80 patients (50 males and 30 females) with
inﬂammatory bowel disease were analyzed. The median
age of patients was 42.7 ± 14.6 years (range 19–74 years).
In 53 patients, ulcerative colitis (UC) was diagnosed and 27
patients fulﬁlled the criteria for Crohn’s disease (CD). The
control group included 100 healthy volunteers—41 males
and 59 females, aged 18–90 (median age, 52.5 ± 20.1
years). The study was approved by the local ethics com-
mittee on human research, and informed consent was
obtained from all patients.
Genomic DNA was isolated from the leukocytes
extracted from the peripheral blood according to
Gustincich’s method [19]. NAT2 genotype identiﬁcation
was performed according to the Spurr’s method [20].
Genomic DNA was subjected to ampliﬁcation using PCR
(polymerase chain reaction) and subsequently the obtained
product was subjected to digestion by restriction enzymes
(RFLP method—restriction fragment length polymor-
phism) in order to detect mutated alleles of the NAT2 gene,
responsible for slow acetylation. Kpn1 and Dde1 enzymes
recognized NAT2*5 allele, Taq 1—NAT2*6, allele and
BamH1—NAT2*7 allele. Lack of restriction sites for a
particular endonuclease suggested presence of a wild-type
allele NAT2*4. Separation of the obtained digestion prod-
ucts was performed by electrophoresis in 8% polyacryl-
amide gel. The obtained bands corresponding with
particular DNA fragments were stained with ethidium
bromide and subsequently analyzed under ultraviolet light.
Having discovered alleles of the following genes of NAT2:
NAT2*4, NAT2*5, NAT2*6, and NAT2*7, speciﬁc geno-
types responsible for slow and fast acetylation phenotypes
were determined. NAT2*4/NAT2*4, NAT2*4/NAT2*5,
NAT2*4/NAT2*6 and NAT2*4/NAT2*7 genotypes deter-
mine fast acetylation phenotypes, while NAT2*5/NAT2*5,
NAT2*5/NAT2*6, NAT2*5/NAT2*7, NAT2*6/NAT2*6,
NAT2*6/NAT2*7 and NAT2*7/NAT2*7 genotypes are
responsible for slow acetylation phenotypes.
The obtained results were subjected to the statistical
analysis. Any statistically important difference in the
incidence of the NAT2 genotypes in the group of patients
with inﬂammatory bowel disease and in the control group
was calculated using v
2. Relative risk of the disease
occurrence was assessed using odds ratio (OR) with an
appropriate conﬁdence interval (CI). Statistical analysis
was performed using the computer program Statistica 6.0.
Results
In the group of patients with inﬂammatory bowel disease,
the majority of them were characterized by a genotype that
resulted in the slow acetylation of xenobiotics (55%).
Subjects with fast acetylation genotype constituted only
45% of the group. No statistically signiﬁcant difference
was observed in the incidence of particular NAT2 geno-
types between the group of patients with inﬂammatory
bowel disease and the control group (Table 1).
Different N-acetyltransferase 2 genotypes in both
groups of patients are shown in Table 2. NAT2*4/NAT2*5
(21.3%) and NAT2*5/NAT2*6 (20%) genotypes were pre-
valent in the IBD group, while NAT2*4/NAT2*6 (30%) and
NAT2*5/NAT2*6 (25%) genotypes were most frequent in
the control group. No statistical difference in the incidence
of speciﬁc NAT2 genotypes was observed in the group of
subjects with IBD and in the control group. Relative risk of
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three times higher in patients with NAT2*5/NAT2*7
genotype (OR = 3.86) and two times higher in subjects
with NAT2*6/NAT2*7 genotypes (OR = 2.53) than in
patients with the other genotypes. However, no statistical
signiﬁcance was reported in other cases. In addition there
were no differences between the control group and patients
with either UC or CD to the distribution of NAT2 geno-
types (Tables 3 and 4).
On the basis of the obtained results of genotyping,
incidence of particular alleles in the patients with IBD and
in the control group was assessed (Table 5). Allele NAT2*5
was predominant in the subjects with IBD (36.2%),
whereas NAT2*6 allele prevailed in the control group
(40%). Relative risk of the occurrence of the IBD,
expressed by the odds ratio, was almost six times higher in
the subjects with NAT2*7 allele (OR = 5.8). This corre-
lation was statistically signiﬁcant (P = 0.005). Such cor-
relation was not observed in patients carrying other alleles
of the NAT2 gene. Relative risk of occurrence of the CD
was ﬁve-fold higher in patients with the NAT2*7 allele
(OR = 5.25); however, in this case no statistical signiﬁ-
cance was shown.
Discussion
The human organism is continuously exposed to noxious
external agents (xenobiotics), including drugs and carcin-
ogenic compounds which may cause numerous diseases.
Xenobiotic metabolizing enzymes, present in the human
body, are the ﬁrst-line defense against environmental
agents. The processes of biotransformation in the organism
are multidirectional and xenobiotics can be transformed
into active or inactive metabolites via an oxidative pathway.
They can also be transformed into harmful compounds with
a potentially pathogenic action [21]. Many xenobiotic
metabolizing enzymes, such as the P-450 cytochrome
group, glutathione transferase or N-acetyltransferase, show
genetic polymorphism, which contributes to marked dif-
ferences in drug metabolism among individuals. There are
numerous reports demonstrating the role of acetylation
Table 1 Distribution of genotypes determining slow and fast acetylation in patients with IBD and in controls
Acetylation genotype Control group (N = 100) IBD (N = 80) UC (N = 53) CD (N = 27)
n (%) n (%) v
2 Pn (%) v
2 Pn (%) v
2 P
Slow acetylators 53 (53%) 44 (55%) 0.07 0.791 29 (54.7%) 0.04 0.839 15 (55.6%) 0.06 0.806
Fast acetylators 47 (47%) 36 (45%) 24 (45.3%) 12 (44.4%)
IBD inﬂammatory bowel disease, UC ulcerative colitis, CD Crohn’s disease
P signiﬁcantly lower (P\0.01)
v
2
Chi
2 test comparing two groups
Table 2 Frequency
distributions of NAT2 genotypes
in the group of patients with
IBD and in the controls
IBD inﬂammatory bowel
disease, OR odds ratio, 95% CI
95% conﬁdence interval
P signiﬁcantly lower (P\0.01)
NAT2 genotype Patients with IBD, N = 80 Controls, N = 100 P OR (95% CI)
n % n %
Fast acetylator
Homozygous
NAT2*4/NAT2*4 7 8.8 4 4 0.647 1.65 (0.465–5.847)
Heterozygous
NAT2*4/NAT2*5 17 21.3 12 12 0.094 1.98 (0.717–5.463)
NAT2*4/NAT2*6 12 15 30 30 0.18 0.41 (0.194–0.865)
NAT2*4/NAT2*7 0 0 1 1 0.909 –
Total 36 45 47 47 0.791 0.92 (0.51–1.66)
Slow acetylator
NAT2*5/NAT2*5 11 13.8 14 14 0.964 0.98 (0.42–2.286)
NAT2*5/NAT2*6 16 20 25 25 0.427 0.75 (0.146–3.838)
NAT2*5/NAT2*7 3 3.8 1 1 0.462 3.86 (0.394–37.77)
NAT2*6/NAT2*6 8 10 12 12 0.671 0.81 (0.317–2.073)
NAT2*6/NAT2*7 2 2.5 1 1 0.896 2.53 (0.225–28.162)
NAT2*7/NAT2*7 4 2.5 0 0 0.079 –
Total 44 47 53 53 0.791 1.08 (0.597–1.952)
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123polymorphism in predisposing towards development of
neoplasm’s, allergies and neurological diseases [22–31].
N-acetylation reaction plays a crucial role in the
detoxiﬁcation of carcinogenic arylamines in the human
body. Both drugs and known environmental carcinogens
are subjected to acetylation. Throughout this process
hydrophobic compounds are converted into hydrophilic
ones and subsequently can be removed by kidneys or in
bile [32, 33].
N-Aminotransferases 1 and 2 Catalyze the N-
Acetylation Reaction
Inﬂammatory bowel disease is becoming a more and more
serious social problem since incidence of the disease is still
growing along with the advancement of our civilization [34,
35]. Patients with IBD may be also at higher risk of devel-
opment of colorectal cancer. According to some reports
individuals with IBD develop colorectal cancer six times
Table 3 Frequency
distributions of NAT2 genotypes
in the group of patients with UC
and in the controls
UC ulcerative colitis, OR odds
ratio, 95% CI 95% conﬁdence
interval
P signiﬁcantly lower (P\0.01)
NAT2 genotype Patients with UC, N = 53 Controls, N = 100 P OR (95% CI)
n % n %
Fast acetylator
Homozygous
NAT2*4/NAT2*4 7 13.2 4 4 0.036 3.6 (0.769–16.827)
Heterozygous
NAT2*4/NAT2*5 11 20.8 12 12 0.149 1.92 (0.785–4.692)
NAT2*4/NAT2*6 6 11.3 30 30 0.01 0.3 (0.117–0.771)
NAT2*4/NAT2*7 0 0 1 1 0.507 –
Total 24 45.3 47 47 0.839 0.93 (0.477–1.813)
Slow acetylator
NAT2*5/NAT2*5 6 11.3 14 14 0.639 0.78 (0.281–2.166)
NAT2*5/NAT2*6 12 22.6 25 25 0.74 0.88 (0.402–1.927)
NAT2*5/NAT2*7 1 1.9 1 1 0.017 1.9 (0.117–30.969)
NAT2*6/NAT2*6 6 11.3 12 12 0.887 0.94 (0.332–1.523)
NAT2*6/NAT2*7 1 1.9 1 1 0.017 1.9 (0.117–30.969)
AT2*7/NAT2*7 3 5.7 0 0 0.09 –
Total 29 54.7 53 53 0.839 1.07 (0.549–2.088)
Table 4 Frequency
distributions of NAT2 genotypes
in the group of patients with CD
and in the controls
CD Crohn’s disease, OR odds
ratio, 95% CI 95% conﬁdence
interval
P signiﬁcantly lower (P\0.01)
NAT2 genotype Patients with CD, N = 27 Controls, N = 100 P OR (95% CI)
n % n %
Fast acetylator
Homozygous
NAT2*4/NAT2*4 0 0 4 4 0.633 –
Heterozygous
NAT2*4/NAT2*5 6 22.2 12 12 0.3 2.09 (0.703–6.214)
NAT2*4/NAT2*6 6 22.2 30 30 0.58 0.67 (0.246–1.829)
NAT2*4/NAT2*7 0 0 1 1 0.08 –
Total 12 44.4 47 47 0.806 0.9 (0.382–2.102)
Slow acetylator
NAT2*5/NAT2*5 5 18.5 14 14 0.777 1.4 (0.455–4.302)
NAT2*5/NAT2*6 5 18.5 25 25 0.655 0.68 (0.233–1.982)
NAT2*5/NAT2*7 2 7.4 1 1 0.218 7.92 (0.69–90.63)
NAT2*6/NAT2*6 2 7.4 12 12 0.729 0.59 (0.124–2.807)
NAT2*6/NAT2*7 0 0 1 1 0.909 –
NAT2*7/NAT2*7 1 3.7 0 0 0.484 –
Total 15 55.6 53 53 0.806 1.11 (0.473–2.604)
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123more frequently than healthy people [36, 37]. However,
other results of different studies suggest that IBD led to the
development of neoplasms only in0.5–2% of cases [38–40].
Research on the correlations of the acetylation rate with
development of IBD is also vital because etiology and
pathogenesis of the disease is still unclear despite many
long-term studies. Genetic determination is believed to
play a role. Numerous studies on the genetic basis of
inﬂammatory bowel disease revealed correlations with
certain chromosomal changes [4, 5, 41]. A clear correlation
between Crohn’s disease and mutations was revealed in the
following genes: NOD2/CARD15 (nucleotide-binding
oligomerization domain 2) gene, also known as (caspase
recruitment domain 15 gene); ATG16L1 (autophagy related
16-like protein); NKX2–3 (NK2 transcription factor related,
locus 3); and in the IL-23 receptor-encoding gene (IL23R)
[1, 4, 37]. Relation between genetic predisposition to the
development of IBD and some HLA class II antigens (B27,
B52, DR2, DR3, DR9, DQ2) was reported [4, 5]. However,
in the literature there are rare and sometimes conﬂicting
data on the inﬂuence of acetylation polymorphism on the
development of the IBD [41–43].
The aim of our study was to investigate the relation
between genetically determined rate of acetylation process
and the risk of developing of inﬂammatory bowel disease
in a Polish population.
Knowledge of this dependence could be helpful in the
explanation of the etiology and pathogenesis of the disease
and may allow us to detect newer predisposing factors.
In our study we observed a slightly higher proportion of
slow acetylators in the group of patients with IBD than in
the group of healthy subjects. It was shown that the fre-
quency of genotypes for the poor and fast acetylation in the
group of patients with IBD reached 55 and 45%, respec-
tively, compared with 53% for slow and 47% for fast
acetylation in the control group. No statistically signiﬁcant
differences in the incidence of NAT2 genotypes for slow
and fast acetylation between the studied groups were found
(P = 0.578). These results were in accordance with the
distribution of acetylation genotypes observed in the Cau-
casian population [44, 45].
Patients with IBD more frequently had NAT2*4/NAT2*5
(21.3%) and NAT2*5/NAT2*6 (20%) genotypes. NAT2*4/
NAT2*6 (30%) and NAT2*5/NAT2*6 (25%) genotypes
were predominant in the control group. No statistically
signiﬁcant difference between frequency of particular
NAT2 genotypes in the group of subjects with IBD and in
the control group was observed. Relative risk of develop-
ment of IBD was three-fold higher for the carriers of
NAT2*5/NAT2*7 allele (OR = 3.86) and two-times higher
for the subjects with NAT2*6/NAT2*7 allele (OR = 2.53)
in comparison to the carriers of other alleles; however, in
both cases no statistical signiﬁcance was showed.
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123Available literature provides ambiguous results of the
studies on the relations between acetylation polymorphism
and the development of the IBD. Mahid et al. assessed
genetic polymorphism of the NAT1 and NAT2 enzymes in
the subjects with colorectal cancer and with IBD. No sta-
tistically signiﬁcant difference between frequency of par-
ticular polymorphic alleles and the increased risk of
development of bowel diseases was reported [42]. On the
other hand, studies performed by Machida et al. revealed
that the NAT2*7B allele, which determines slow acetyla-
tion, is related to Crohn’s disease in the Japanese popula-
tion (OR = 2.8; P = 0.013) [41].
Results of our study showed that relative risk of devel-
opment of IBD, which was expressed by the odds ratio, was
almost six times higher in NAT2*7 allele carriers
(OR = 5.8). The correlation was statistically signiﬁcant
(P = 0.005). No such correlation was found in the case of
patients with other alleles of the NAT2 gene. Relative risk
of occurrence of the CD was ﬁve-fold higher in patients
with NAT2*7 allele (OR = 5.25); however, in this case no
statistical signiﬁcance was shown.
Therefore, it can be assumed that polymorphism of the
NAT2 enzyme is one of the agents predisposing to the
development of the disease.
There are far more reports on the role of NAT2 poly-
morphism in the development of neoplasms [46–49].
Gastrointestinal cancers such as gastric, duodenal, colo-
rectal and pancreatic cancers are among the most frequent
malignant tumors. Colorectal cancer is the most prevalent
tumor and the second most lethal among all neoplasm’s
that occur in the Polish population [50]. NAT2 metabolizes
carcinogenic compounds: heterocyclic aromatic amines
and polycyclic aromatic hydrocarbons, which are produced
in the course of meat processing such as grilling or frying.
Both smoking and eating fried meat may lead to the
development of this tumor. Lila et al. reported that the
NAT1 and NAT2 fast genotypes may contribute jointly to
individual susceptibility and may play an important role in
colorectal cancer associated with red meat and possibly
also exposure to environmental tobacco smoke [25].
However, according to Kiyohra et al., the relation between
NAT2 polymorphism and colorectal cancer is rather
insigniﬁcant. On the other hand, there is still correlation
between development of colorectal cancer, meat con-
sumption, fast acetylation by NAT2 and high activity of
CYP1A2. Coexistence of the NAT2 genotype, determining
fat acetylation and CYP1A2, responsible for fast
N-hydroxylation, increase the risk of carcinoma in people
eating fried meat (OR = 2.8) [22].
Apart from the potential inﬂuence on the development
of certain diseases, genetically determined acetylation
polymorphism may also affect pharmacokinetic reactions
of several drugs. In some patients, especially in the case of
chronic treatment, therapeutic effects may be either
increased or decreased or interactions between medicines
and hazardous side effects may occur [51]. N-acetyltrans-
ferase metabolizes a number of commonly used drugs, such
as sulphasalazine, used in patients with rheumatoid arthritis
and inﬂammatory bowel diseases. Kumagal et al. studied
the effectiveness of the drug depending on the NAT2
genotype. It was shown that, depending on the NAT2
genotype, a proportion of sulphapiridine (an active com-
ponent of the sulphasalazine) in its acetylated form was
found to be different. This difference in the proportion of
the drug and its metabolite is the evidence of different
efﬁcacy of the sulphasalazine in patients with different
genotypes [23].
Sulphasalazine is frequently used in the treatment of
inﬂammatory bowel disease. Chen et al. studied NAT2
polymorphism and its correlation with the side effects of
sulphasalzine in patients with IBD. It was revealed that
patients with IBD who were characterized by the slow
acetylation genotype without the wild-type NAT2*4 allele
experienced side effects of the drug more frequently (36%)
than individuals with fast acetylation genotype, including
at least 1 wild-type NAT2*4 allele (11%), but the results
were found to be not statistically signiﬁcant [52].
Knowledge of genetically determined individual differ-
ences in the xenobiotic metabolism is an important clinical
problem considering both individual pharmacotherapy and
relations between the acetylation genotype and the risk of
development of diseases with an unknown etiology,
including inﬂammatory bowel disease.
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